Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Bold values are considered as significant (p < 0.05)Fazekas score ≤ 1Group A (N = 173)Fazekas score ≥ 2Group B (N = 44)P valueDemographics Age, years [median (IQR)]55 (47 to 61)63 (56 to 65) < 0.001 Female sex [n, (%)]61 (36)20 (44)0.268 Hypertension [n, (%)]77 (45)35 (78) < 0.001 Diabetes mellitus [n, (%)]19 (11)8 (18)0.223 Hypercholesterolemia [n, (%)]83 (48)31 (69)0.014 Hypertriglyceridemia [n, (%)]14 (8)6 (13)0.284 Atrial fibrillation [n, (%)]10 (6)2 (4)1.000 BMI kg/m^2 [median (IQR)]25 (23 to 28)25 (23 to 30)0.823Smoking [n, (%)] Current smoker64 (37)21 (47)0.358 Ex smoker34 (20)10 (22) Previous TIA/ischemic stroke [n, (%)]20 (12)14 (31) < 0.001Type of ischemic event [n, (%) Ischemic stroke113 (66)37 (82)0.169 TIA59 (34)8 (18)Admission therapy Anticoagulation onadmission [n, (%)]6 (4)2 (4)0.617 Antiplatelet therapy onadmission [n, (%)]19 (11)14 (31) < 0.001 Lipid-lowering therapy [n, (%)]25 (15)16 (36) < 0.001Stroke characteristics NIHSS on admission [median (IQR)]1 (0 to 4)2 (0 to 4)0.656 NIHSS on discharge [median (IQR)]0 (0 to 1)0 (0 to 1)0.480 mRS pre admission [median (IQR)]0 (0 to 0)0 (0 to 0)0.403 mRS on discharge [median (IQR)]0 (0 to 1)0 (0 to 1)0.188TOAST etiology [n, (%)] LAA20 (12)5 (11)0.027 CE54 (31)5 (11) Lacunar17 (10)10 (22) Other15 (9)3 (7) Cryptogenic66 (38)22 (49) Right-to-left atrial shunt [n, (%)]46 (27)5 (11)0.025Blood biomarkers Lpa > 50 mg/dL [n, (%)]29 (17)15 (33)0.014 Total cholesterol levels [median (IQR)]201 (171 to 234)226 (185 to 248)0.017 HDL cholesterol [median (IQR)]53 (43 to 61)49 (42 to 56)0.307 Non HDL cholesterol [median (IQR)]150 (117 to 179)172 (135 to 193)0.014 Fibrinogen [median (IQR)]301 (244 to 363)306 (259 to 365)0.925 Hyperuricemia [n, (%)]26 (15)15 (33)0.005 Vitamin D deficiency [n, (%)]73 (42)20 (44)0.809 Vitamin B12 deficiency [n, (%)]25 (15)7 (16)0.864 Folate deficiency [n, (%)]16 (9)9 (20)0.045 Homocystein [median (IQR)]13 (10 to 15)13 (11 to 16)0.274
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Lipoprotein-a and white matter abnormalities: predicting small vessel disease in young patients with ischemic cerebrovascular events
Study design awaiting verification · Journal of Neurology · 2025
Original publication title
Lipoprotein-a and white matter abnormalities: predicting small vessel disease in young patients with ischemic cerebrovascular events
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Post-stroke cognitive impairment (PSCI) affects 15 to 70% of ischemic stroke survivors, with vascular dementia contributing significantly to long-term disability. Lipoprotein(a) [Lp(a)] has emerged as a key risk factor for cardiovascular and cerebrovascular diseases, but its role in cerebral small vessel disease (cSVD) remains unclear. This study investigates the association between elevated Lp(a) levels and Fazekas scores (≥ 2), a marker of white matter hyperintensities (WMHs) indicative of cSVD, in young patients (< 65 years) with ischemic stroke or transient ischemic attack (TIA).
Source: IntroductionAbstract: What methods does the paper describe?
We retrospectively analysed data of 217 patients with ischemic stroke/TIA, age 18 to 65, and Lp(a) measurement within four weeks of the event. Data included clinical history, imaging (MRI Fazekas scores), and Lp(a) levels (> 50 mg/dL). Multivariable logistic regression and ROC analysis were performed to identify predictors of higher Fazekas scores.
Source: MethodsAbstract: Results
Elevated Lp(a) levels were independently associated with Fazekas scores ≥ 2 (OR 2.83, 95% CI 1.13 to 7.10, p = 0.03) alongside older age, hypertension, prior stroke/TIA, and elevated non-HDL cholesterol. The predictive model demonstrated high accuracy (AUC = 0.81). Patients with elevated Lp(a) exhibited greater WMH burden, indicating advanced small vessel damage.
Source: ResultsAbstract: Conclusions
Elevated Lp(a) levels are a significant biomarker for WMHs and cSVD in young stroke patients, offering prognostic value beyond traditional risk factors. Incorporating Lp(a) testing into routine stroke evaluations could enable early identification and tailored management strategies to mitigate further vascular damage and cognitive decline.
Source: ConclusionsAuthors’ abstract
Introduction
Post-stroke cognitive impairment (PSCI) affects 15 to 70% of ischemic stroke survivors, with vascular dementia contributing significantly to long-term disability. Lipoprotein(a) [Lp(a)] has emerged as a key risk factor for cardiovascular and cerebrovascular diseases, but its role in cerebral small vessel disease (cSVD) remains unclear. This study investigates the association between elevated Lp(a) levels and Fazekas scores (≥ 2), a marker of white matter hyperintensities (WMHs) indicative of cSVD, in young patients (< 65 years) with ischemic stroke or transient ischemic attack (TIA).
Methods
We retrospectively analysed data of 217 patients with ischemic stroke/TIA, age 18 to 65, and Lp(a) measurement within four weeks of the event. Data included clinical history, imaging (MRI Fazekas scores), and Lp(a) levels (> 50 mg/dL). Multivariable logistic regression and ROC analysis were performed to identify predictors of higher Fazekas scores.
Results
Elevated Lp(a) levels were independently associated with Fazekas scores ≥ 2 (OR 2.83, 95% CI 1.13 to 7.10, p = 0.03) alongside older age, hypertension, prior stroke/TIA, and elevated non-HDL cholesterol. The predictive model demonstrated high accuracy (AUC = 0.81). Patients with elevated Lp(a) exhibited greater WMH burden, indicating advanced small vessel damage.
Conclusions
Elevated Lp(a) levels are a significant biomarker for WMHs and cSVD in young stroke patients, offering prognostic value beyond traditional risk factors. Incorporating Lp(a) testing into routine stroke evaluations could enable early identification and tailored management strategies to mitigate further vascular damage and cognitive decline.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00415-025-13111-2.
Publication and source details
Original title: Lipoprotein-a and white matter abnormalities: predicting small vessel disease in young patients with ischemic cerebrovascular events
Paola Caruso; Marco Liccari; Gabriele Prandin; Pierandrea Vinci; Federica Pellicori; Nicola Fiotti; Emiliano Panizon; Giovanni Furlanis; Marcello Naccarato; Gianni Biolo; Paolo Manganotti
Journal of Neurology · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di TriesteOpen access funding provided by Università degli Studi di Trieste within the CRUI-CARE Agreement.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T05:20:39.113843+00:00
DOI: 10.1007/s00415-025-13111-2 · PMC12055645